Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s ...

The US Food and Drug Administration (FDA) approved San Diego, USA-based LENZ Therapeutics’ VIZZ (aceclidine ophthalmic ...

After nearly 27 years as a division of Swiss giant Novartis, generics and biosimilars specialist Sandoz (SWX: SDZ) went its ...

England has agreed to commission the use of Hemlibra (emicizumab) as a prophylactic treatment for patients of all ages with ...

German healthcare and crop sciences giant Bayer (BAYN DE) saw its share close up 2.8% at 28.12 euros, after it provided an ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...

Swiss pharma giant Roche announced positive five-year efficacy, safety and durability data from the Phase III Portal study, a ...

US mRNA specialist Moderna has announced that the UK Court of Appeal has upheld the validity of its EP'949 patent.

For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation ...

US mRNA specialist Moderna has today reported financial results and provided business updates for the second quarter of 2025, ...

Frazier Life Sciences (FLS), a US investment firm focused on innovative therapeutics, has announced the closing of its ...

The US Food and Drug Administration (FDA) is requiring safety labeling changes to all opioid pain medications to better ...